PHASE I CO-DEVELOPMENT AGREEMENTDevelopment Agreement • August 11th, 2014 • Oncothyreon Inc. • Services-commercial physical & biological research • Delaware
This Phase I Co-Development Agreement (the “Agreement”), entered into as of May 28, 2014 (the “Effective Date”), is made by and between Celldex Therapeutics, Inc., a Delaware corporation, having offices at 119 Fourth Avenue, Needham, MA 02494 (“Celldex”), and Oncothyreon Inc., a Delaware corporation, having offices at 2601 Fourth Ave., Suite 500, Seattle WA 98121 (“Oncothyreon”).
